142 related articles for article (PubMed ID: 38191492)
1. Molecular profiling of biliary tract cancers reveals distinct genomic landscapes between circulating and tissue tumor DNA.
Astier C; Ngo C; Colmet-Daage L; Marty V; Bawa O; Nicotra C; Ngo-Camus M; Italiano A; Massard C; Scoazec JY; Smolenschi C; Ducreux M; Hollebecque A; Postel-Vinay S
Exp Hematol Oncol; 2024 Jan; 13(1):2. PubMed ID: 38191492
[TBL] [Abstract][Full Text] [Related]
2. Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures.
Mody K; Jain P; El-Refai SM; Azad NS; Zabransky DJ; Baretti M; Shroff RT; Kelley RK; El-Khouiery AB; Hockenberry AJ; Lau D; Lesinski GB; Yarchoan M
JCO Precis Oncol; 2022 Jun; 6():e2100510. PubMed ID: 35675577
[TBL] [Abstract][Full Text] [Related]
3. Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations.
Wardell CP; Fujita M; Yamada T; Simbolo M; Fassan M; Karlic R; Polak P; Kim J; Hatanaka Y; Maejima K; Lawlor RT; Nakanishi Y; Mitsuhashi T; Fujimoto A; Furuta M; Ruzzenente A; Conci S; Oosawa A; Sasaki-Oku A; Nakano K; Tanaka H; Yamamoto Y; Michiaki K; Kawakami Y; Aikata H; Ueno M; Hayami S; Gotoh K; Ariizumi SI; Yamamoto M; Yamaue H; Chayama K; Miyano S; Getz G; Scarpa A; Hirano S; Nakamura T; Nakagawa H
J Hepatol; 2018 May; 68(5):959-969. PubMed ID: 29360550
[TBL] [Abstract][Full Text] [Related]
4. The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer.
Berchuck JE; Facchinetti F; DiToro DF; Baiev I; Majeed U; Reyes S; Chen C; Zhang K; Sharman R; Uson Junior PLS; Maurer J; Shroff RT; Pritchard CC; Wu MJ; Catenacci DVT; Javle M; Friboulet L; Hollebecque A; Bardeesy N; Zhu AX; Lennerz JK; Tan B; Borad M; Parikh AR; Kiedrowski LA; Kelley RK; Mody K; Juric D; Goyal L
Ann Oncol; 2022 Dec; 33(12):1269-1283. PubMed ID: 36089135
[TBL] [Abstract][Full Text] [Related]
5. Molecular Profiling in Daily Clinical Practice: Practicalities in Advanced Cholangiocarcinoma and Other Biliary Tract Cancers.
Lamarca A; Kapacee Z; Breeze M; Bell C; Belcher D; Staiger H; Taylor C; McNamara MG; Hubner RA; Valle JW
J Clin Med; 2020 Sep; 9(9):. PubMed ID: 32899345
[TBL] [Abstract][Full Text] [Related]
6. Circulating Tumor DNA Profiling of Advanced Biliary Tract Cancers.
Mody K; Kasi PM; Yang J; Surapaneni PK; Bekaii-Saab T; Ahn DH; Mahipal A; Sonbol MB; Starr JS; Roberts A; Nagy R; Lanman R; Borad MJ
JCO Precis Oncol; 2019 Dec; 3():1-9. PubMed ID: 35100741
[TBL] [Abstract][Full Text] [Related]
7. Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets.
Weinberg BA; Xiu J; Lindberg MR; Shields AF; Hwang JJ; Poorman K; Salem ME; Pishvaian MJ; Holcombe RF; Marshall JL; Morse MA
J Gastrointest Oncol; 2019 Aug; 10(4):652-662. PubMed ID: 31392046
[TBL] [Abstract][Full Text] [Related]
8. KRAS Allelic Variants in Biliary Tract Cancers.
Moffat GT; Hu ZI; Meric-Bernstam F; Kong EK; Pavlick D; Ross JS; Murugesan K; Kwong L; De Armas AD; Korkut A; Javle M; Knox JJ
JAMA Netw Open; 2024 May; 7(5):e249840. PubMed ID: 38709532
[TBL] [Abstract][Full Text] [Related]
9. Current Role and Future Perspectives of Immunotherapy and Circulating Factors in Treatment of Biliary Tract Cancers.
Conci S; Catalano G; Roman D; Zecchetto C; Lucin E; De Bellis M; Tripepi M; Guglielmi A; Milella M; Ruzzenente A
Int J Med Sci; 2023; 20(7):858-869. PubMed ID: 37324191
[TBL] [Abstract][Full Text] [Related]
10. Liquid Biopsy from Bile-Circulating Tumor DNA in Patients with Biliary Tract Cancer.
Han JY; Ahn KS; Kim TS; Kim YH; Cho KB; Shin DW; Baek WK; Suh SI; Jang BC; Kang KJ
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572808
[TBL] [Abstract][Full Text] [Related]
11. Exome sequencing of 22 genes using tissue from patients with biliary tract cancer.
Høgdall D; Larsen OF; Linnemann D; Svenstrup Poulsen T; Høgdall EV
APMIS; 2020 Jan; 128(1):3-9. PubMed ID: 31628675
[TBL] [Abstract][Full Text] [Related]
12. Circulating Cell-Free DNA-Based Comprehensive Molecular Analysis of Biliary Tract Cancers Using Next-Generation Sequencing.
Csoma SL; Bedekovics J; Veres G; Árokszállási A; András C; Méhes G; Mokánszki A
Cancers (Basel); 2022 Jan; 14(1):. PubMed ID: 35008396
[TBL] [Abstract][Full Text] [Related]
13. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
[TBL] [Abstract][Full Text] [Related]
14. Practical guidelines for molecular testing of cholangiocarcinoma in clinical practice: Italian experts' position paper.
Fassan M; Angerilli V; Normanno N; Pruneri G; Marchetti A; Grillo F; Tonini G; Scarpa A; Rimassa L
Crit Rev Oncol Hematol; 2024 Feb; 194():104224. PubMed ID: 38211900
[TBL] [Abstract][Full Text] [Related]
15. Mutational spectrum and precision oncology for biliary tract carcinoma.
Lin J; Cao Y; Yang X; Li G; Shi Y; Wang D; Long J; Song Y; Mao J; Xie F; Bai Y; Zhang L; Yang X; Wan X; Wang A; Guan M; Zhao L; Hu K; Pan J; Huo L; Lu X; Mao Y; Sang X; Zhang H; Wang K; Wang X; Zhao H
Theranostics; 2021; 11(10):4585-4598. PubMed ID: 33754015
[No Abstract] [Full Text] [Related]
16. PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair system.
Zimmer K; Kocher F; Untergasser G; Kircher B; Amann A; Baca Y; Xiu J; Korn WM; Berger MD; Lenz HJ; Puccini A; Fontana E; Shields AF; Marshall JL; Hall M; El-Deiry WS; Hsiehchen D; Macarulla T; Tabernero J; Pichler R; Khushman M; Manne U; Lou E; Wolf D; Sokolova V; Schnaiter S; Zeimet AG; Gulhati P; Widmann G; Seeber A
NPJ Precis Oncol; 2023 Jul; 7(1):64. PubMed ID: 37400502
[TBL] [Abstract][Full Text] [Related]
17. Novel insights into molecular and immune subtypes of biliary tract cancers.
Bramel ER; Sia D
Adv Cancer Res; 2022; 156():167-199. PubMed ID: 35961699
[TBL] [Abstract][Full Text] [Related]
18. New genomic landscapes and therapeutic targets for biliary tract cancers.
Simbolo M; Fassan M; Mafficini A; Lawlor RT; Ruzzenente A; Scarpa A
Front Biosci (Landmark Ed); 2016 Jan; 21(4):707-18. PubMed ID: 26709801
[TBL] [Abstract][Full Text] [Related]
19. Effect of comprehensive cancer genomic profiling on therapeutic strategies and clinical outcomes in patients with advanced biliary tract cancer: A prospective multicenter study.
Takada K; Kubo T; Kikuchi J; Yoshida M; Murota A; Arihara Y; Nakamura H; Nagashima H; Tanabe H; Sugita S; Tanaka Y; Miura A; Ohhara Y; Ishiguro A; Yokouchi H; Kawamoto Y; Mizukami Y; Ohnishi H; Kinoshita I; Sakurai A
Front Oncol; 2022; 12():988527. PubMed ID: 36119486
[TBL] [Abstract][Full Text] [Related]
20. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.
Churi CR; Shroff R; Wang Y; Rashid A; Kang HC; Weatherly J; Zuo M; Zinner R; Hong D; Meric-Bernstam F; Janku F; Crane CH; Mishra L; Vauthey JN; Wolff RA; Mills G; Javle M
PLoS One; 2014; 9(12):e115383. PubMed ID: 25536104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
